How Novartis are predicting #Antibody stability
Antibody stability: Do you wish you could predict the likelihood of your protein aggregating?
Novartis have developed a rapid, in silico technology which predicts the aggregation propensity of proteins – The Developability Index.
Dr Bernhard Helk, the Global Executive Director of Technology Development at Novartis, presented this work at the 7th annual European antibody congress 2011, where he explained how hot-spots for aggregation can be identified based on the dynamic exposure of spatially-adjacent hydrophobic amino acids with SAP technology (Spatial Aggregation Propensity). He also went on to show how SAP technology can be used in protein engineering, and also in the design of antibody drug conjugates.
Do you want to find out more?